Eddie Hickman
Stock Analyst at Guggenheim
(3.47)
# 812
Out of 4,826 analysts
16
Total ratings
43.75%
Success rate
8.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $47.42 | +77.14% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.66 | +809.37% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.00 | +175.00% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $11.40 | +180.70% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $6.50 | +438.46% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.55 | +674.19% | 3 | Jan 17, 2025 | |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $47.42
Upside: +77.14%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.66
Upside: +809.37%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.00
Upside: +175.00%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $11.40
Upside: +180.70%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $6.50
Upside: +438.46%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.55
Upside: +674.19%